ReviewArquivos brasileiros de cardiologia2025
Medical Reversals, Spins and Divergent Results in Cardiology Trials.
Review in Arquivos brasileiros de cardiologia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular medicine has witnessed remarkable breakthroughs, yet even highly regarded interventions can be undermined by flawed reasoning, excessive mechanistic assumptions, and the selective reporting of data. This article examines crucial pitfalls in contemporary cardiology, such as medical reversals, the impact of spin, and how bayesian methods can offer greater clarity in evaluating evidence, as they integrate prior knowledge with new data to generate more probabilistic, context-driven conclusions. This review advocates for a measured, critical approach to research appraisal, cautioning cardiologists against uncritically accepting trial conclusions at face value. Adopting this vigilant stance will help ensure that emerging therapies and interventions genuinely advance patient outcomes, guiding physicians toward more credible, transparent, and beneficial strategies in the ever-evolving field of cardiovascular medicine. Such vigilance is important to preserve the integrity of scientific inquiry and meaningful progress in patient care. This approach promotes reliability of published data.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.